NVO News and Headlines - Novo Nordisk A/S
The stock of Novo Nordisk A/S (NYSE:NVO, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line,
The prospects for several drug makers—and their investors—are likely to be affected as clinical trial results for key medications are reported this year. For an example of what a bad outcome can have on a company's share price, look no further than what happened to Eli Lilly and Co.'s (LLY) stock on Monday when the Indianapolis-based pharma company reported mixed results in tests of its Alzheimer's treatment. On the news, Lilly's shares took a haircut of nearly $20 to about $188.
Eli Lilly will get a chance to redeem itself when it also gets a readout this year on its
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.
Abbott Laboratories (ABT) has a market cap of $193 billion. It has outperformed the S&P 500 by 12.01% over the past year.
As of Tuesday, the share price was 76.87% above the 52-week low and 5.36% below the 52-week high.
The company, which manufactures medical devices and adult and pediatric nutritional products, has a GuruFocus profitability rating of 7 out of 10. The return on equity of 10.9%
Danish pharmaceutical giant Novo Nordisk AS (NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.
Novo obtains the know-how with the $1.8 billion purchase of Emisphere Technologies Inc. (EMIS), a New Jersey-based company that specializes in drug delivery. Emisphere trades over the counter.
Novo recently used the Emisphere technology under license to develop its diabetes drug, Rybelsus—the first and only oral type of a class of drugs called glucagon-like peptide agonists, according to an article in FiercePharma. GL-1 drugs not only improve blood sugar control, but may
In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (BIIB), Novo Nordisk A/S (NVO), ResMed Inc. (RMD) and Illumina Inc. (ILMN) according to the All-in-One Screener, a Premium feature of GuruFocus.
U.S. markets slip as coronavirus cases increase around the globe
On Monday, the Dow Jones Industrial Average closed at 28,195.42, down 410.89 points from last Friday's close of 28,606.31 as surging coronavirus cases around the globe dampened investor sentiment.
According to Johns Hopkins University statistics, global cases of Covid-19
As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are AmerisourceBergen Corp. (ABC), Chemed Corp. (CHE), Neogen Corp. (NEOG), Novo Nordisk A/S (NVO) and ResMed Inc. (RMD) according to the All-in-One Screener, a Premium feature of GuruFocus.
U.S. markets slip on renewed fears of coronavirus spread
On Tuesday, the Dow Jones Industrial Average closed at 27,451.81, down 132.25 points from Monday's close of 27,584.06. The 30-stock index traded at an intraday low of 27,338 earlier in
According to the GuruFocus All-in-One Screener, a Premium feature, the stocks of the following guru-owned health care companies have outperformed the S&P 500 Index over the past 12 months through July 10.
UnitedHealth Group Inc. (UNH) has a market cap of $287.94 billion. It has outperformed the S&P 500 by 7.42% over the past year.
Shares are trading with a price-earnings ratio of 7.08. As of Friday, the share price was 61.74% above the 52-week low and 3.87% below the 52-week high.
The company has a GuruFocus profitability rating of 8 out of 10. The return on
Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according to a report from the Westhealth Policy Center. At the other end of the spectrum were Abbott Laboratories (ABT) and Easai Co. (TSE:4523).
In simplest terms, ROIC is a profitability ratio that indicates just how efficient a company is turning capital into profit. It measures the return that an investment generates for those who have provided capital (i.e., bondholders and stockholders).
ROIC can be important to investors because it is a key
Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc. (BMRN) has the most to gain. If the company’s Roctavian gets greenlighted by the Food and Drug Administration, it will become the first gene therapy for one of the world’s highest-profile inherited diseases, hemophilia A.
Hemophilia is a rare hereditary bleeding disorder that occurs in a relatively small number of patients around the world. Its cause is a missing or deficient protein needed for blood clotting. Hemophilia A occurs in one in 5,000 live male births. It is about four times as common
In light of Novavax Inc. (NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (ALXN), Novo Nordisk A/S (NVO), Galapagos NV (GLPG), Regeneron Pharmaceuticals Inc. (REGN) and Vertex Pharmaceuticals Inc. (VRTX).
Novavax continues big surge on coronavirus vaccine federal aid
Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of
Growing earnings can often push share prices up. The S&P 500 Index, which is a benchmark for the U.S. market, has grown its annual earnings per share (not adjusted for inflation) by about 6.5% every year over the past five years. On the tailwind of this, the share price of the index increased by nearly 49% over the past five years, closing at a price of $3,003.37 on March 3, 2020.
Past performance is not a guarantee of future results, but it does indicate that a company has a better foundation on which to grow.
As a result of strong
"When you have to make a choice and don’t make it, that is in itself a choice."
- William James
One evening a Cherokee elder told his grandson about a battle that goes on inside people. He said, “My son, the battle is between two “wolves” inside us all. One is Evil. It is anger, envy, jealousy, sorrow, regret, greed, arrogance, self-pity, guilt, resentment, inferiority, lies, false pride, superiority, and ego. The other is Good. It is joy, peace, love, hope, serenity, humility, kindness, benevolence, empathy, generosity, truth, compassion, and faith.” The grandson thought about
In light of the coronavirus outbreak in China, five U.S. and Asian health care companies with good financial strength and profitability are Edwards Lifesciences Corp. (EW), Novo Nordisk A/S (NVO), Guangdong Zhongsheng Pharmaceutical Co. Ltd. (SZSE:002317), DongKook Pharmaceutical Co. Ltd. (XKRX:086450) and Bumrungrad Hospital PCL (BKK:BH) according to the All-in-One Screener, a major GuruFocus Premium feature.
Dow tumbles on increased coronavirus fears, suggesting opportunities in health care
On Monday, the Dow Jones Industrial Average closed at 28,533.90, down 455.83 points from Friday’s close of 28,989.73, on increased fears over the coronavirus’ impact to the global
According to the All-in-One Screener, a GuruFocus Premium feature, four health care companies with high financial strength and profitability are Biogen Inc. (BIIB), Illumina Inc. (ILMN), Masimo Corp. (MASI) and Novo Nordisk A/S (NVO).
China agrees to purchase $200 billion worth of U.S. goods as part of trade deal, including pharma products
On Wednesday, Chinese President Xi Jinping and U.S. President Trump signed “phase one” of their landmark trade deal, which includes China purchasing $200 billion in U.S. goods over the next two years. Manufactured goods, which include industrial equipment, electric equipment and pharmaceutical products, account
Denmark-based Novo Nordisk (OCSE:NOVO B) (NVO) is a global developer of drugs to treat chronic diseases, including diabetes, obesity and hemophilia. The company has sales in 170 countries.
Diabetes and obesity together accounted for 84% of the company’s fiscal 2018 sales. The U.S. is the most significant revenue contributor (49% as of 2018 sales), followed by Europe (19%), Africa, Asia, Middle East and Oceania (11%) and China (10%). Although we are typically cautious about the pipeline risk associated with investing in pharma, we appreciate the strategic focus, dominant market positions and secular growth opportunities at Novo Nordisk.
The company dominates
"The two most powerful warriors are patience and time.” - Leo Tolstoy
“Great leadership is about continual change. An outstanding leader is always seeking opportunities in failure and always seeking improvement from success. Patience is key, but does not guarantee long-term prosperity.” - Iwasaki YatarŠ
In Japan, the Sengoko period (or, as translated into English, “The Age of Warring States”) ran from roughly the mid-15th century and ended with the Battle of Sekigahara in 1603. During that time, Japan was engaged in nearly constant civil wars as a series of very powerful regional leaders known as d'imyo battled
Dr. Jennifer Schneider, the president ofÂ Livongo Health Inc. (LVGO),Â couldn’t have been more succinct in describing what the Mountain View, California-based company does: “make it easier for members to stay healthy." In doing so, the company also hopes to put its investors in the pink.
Livongo is an information technology company that uses its software platform to improve the health of patients with chronic conditions, including hypertension, diabetes and weight issues.
The company had a strong opening when it went public on July 25. Its stock climbed 60% above the initial public offering,
Sanofi SA's (SNY) newly minted CEO is looking under the hood to figure out what’s needed to get the company in gear. Shareholders are hoping he’s successful. The French pharmaceutical giant has been stuck in neutral for a while, with its shares off a few dollars from where they were two years ago. In defense of Sanofi’s performance, the stock has outperformed the SPDR S&P Pharmaceuticals Exchange-Traded Fund (XPH)
Paul Hudson, 51, who came to Sanofi from Novartis early last month, has been on what he calls a “listening tour,” site to site, country to country, according to an Oct.
As investors anticipate the next round of trade talks between the U.S. and China, several opportunities exist in European markets. According to the High Quality Screener, one of our predefined screens within the All-in-One Screener, five European health care companies with good business quality are BioGaia AB (OSTO:BIOG B), CellaVision AB (OSTO:CEVI), Diasorin SpA (MIL:DIA), Novo Nordisk A/S (NVO)(OCSE:NOVO B) and Vitrolife AB (OSTO:VITR).
Dow trades higher, but European markets decline ahead of US-China trade talks
Although the Dow Jones Industrial Average traded at an intraday high of 26,424.31, up 260.27 points from Tuesday’s close of 26,164.04, the 30-stock
In light of rekindling trade concerns between the U.S. and China, four U.S. stocks with the financial strength and profitability to weather the storm are Apple Inc. (AAPL), Novo Nordisk A/S (NVO), Manhattan Associates Inc. (MANH) and Paychex Inc. (PAYX).
Dow tumbles as White House mulls investment ban on China
On Friday, the Dow Jones Industrial Average closed at 26,820.25, down 70.87 from Thursday’s close of 26,891.12 and 192.29 from the intraday high of 27,012.54. CNBC columnists Eamon Javers and Yun Li reported that sources familiar with the matter said the White House is “weighing some curbs on U.S. investments
|2021-04-13 $ 70.77 (1.89%)|
AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal - www.zacks.com
|2021-04-01 $ 67.66 (0.36%)|
Top Analyst Reports for Facebook, Adobe & Novo Nordisk - www.zacks.com
|2021-03-30 $ 67.92 (-0.75%)|
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now - www.zacks.com
Novo Nordisk A/S Stock Is Estimated To Be Fairly Valued - GuruFocus.com
Forget Altria: Here Are 3 Better Dividend Stocks - www.fool.com
|2021-03-19 $ 70.35 (-0.79%)|
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk - www.zacks.com
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic - www.zacks.com
|2021-03-18 $ 70.91 (-1.21%)|
Top Analyst Reports for Novo Nordisk, NextEra & 3M Company - www.zacks.com
|2021-02-26 $ 71.25 (-1.51%)|
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss - www.zacks.com
|2021-02-22 $ 72.75 (-1.8%)|
|2021-02-19 $ 74.08 (-1.35%)|
|2021-02-04 $ 71.63 (-1.08%)|
|2021-02-03 $ 72.41 (2.03%)|
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates - www.zacks.com
|2021-01-29 $ 69.6 (-1.42%)|
Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance - www.zacks.com
|2021-01-28 $ 70.6 (0.9%)|
|2021-01-27 $ 69.97 (-4.5%)|
Top Research Reports for Facebook, Novo Nordisk & SAP - www.zacks.com
|2021-01-21 $ 72.52 (0.75%)|
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead? - www.zacks.com
|2021-01-19 $ 73.02 (1.37%)|
|2021-01-13 $ 70.9 (2.26%)|
Top Analyst Reports for Amazon, Thermo Fisher & Eli Lilly - www.zacks.com
|2021-01-12 $ 69.33 (-1.55%)|
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand - www.zacks.com
|2021-01-06 $ 68.93 (-2.6%)|
AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease - www.zacks.com
|2021-01-05 $ 70.77 (-0.92%)|
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance - www.zacks.com
|2020-12-30 $ 70.2 (-0.54%)|
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU - www.zacks.com
|2020-12-21 $ 71.9 (-2.57%)|
Top Analyst Reports for Alphabet, Comcast & Accenture - www.zacks.com
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU - www.zacks.com
|2020-12-10 $ 69.28 (-1.38%)|
Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study - www.zacks.com
|2020-12-09 $ 70.25 (2.44%)|
|2020-12-08 $ 68.58 (0.54%)|
Top Research Reports for Alibaba, QUALCOMM & Novo Nordisk - www.zacks.com
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy - www.zacks.com
How You Can Profit From the Best-Managed Drugmaker on Earth - www.fool.com
|2020-12-07 $ 68.21 (0.59%)|
FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda - www.zacks.com
FDA Approves Label Expansion of Novo Nordisk's (NVO) Saxenda - www.zacks.com
|2020-12-01 $ 67.51 (0.57%)|
AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure - www.zacks.com
|2020-11-30 $ 67.13 (-0.61%)|
|2020-11-25 $ 66.14 (0.33%)|
Is Novo Nordisk (NVO) a Suitable Stock for Value Investors? - www.zacks.com
|2020-11-18 $ 66.52 (-0.31%)|
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint - www.zacks.com
|2020-11-16 $ 67.29 (-1.16%)|
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study - www.zacks.com
|2020-11-12 $ 68.22 (0.77%)|
Novo Acquisition Gives It Unique Drug Delivery Technology - GuruFocus.com
|2020-11-11 $ 67.7 (0.25%)|
Top Research Reports for Facebook, Verizon & Toyota Motor - www.zacks.com
|2020-11-10 $ 67.94 (-3.44%)|
|2020-11-09 $ 67.94 (-3.44%)|
|2020-11-05 $ 71.56 (2.27%)|
Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2% - www.zacks.com
|2020-10-30 $ 63.89 (-3.68%)|
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss - www.zacks.com
|2020-10-19 $ 70.78 (-0.34%)|
SNY or NVO: Which Is the Better Value Stock Right Now? - www.zacks.com
|2020-10-15 $ 70.57 (-1.62%)|
|2020-10-13 $ 73.18 (-0.6%)|
|2020-10-09 $ 72.07 (1.17%)|
Novo Nordisk Raises Sales & Operating Profit Outlook for 2020 - www.zacks.com
|2020-10-06 $ 69.16 (-1.37%)|
|2020-10-02 $ 68.66 (-0.85%)|
$NVO - Revisiting Novo Nordisk. Revisiting Novo Nordisk - seekingalpha.com
|2020-09-21 $ 68.99 (-0.65%)|
The Zacks Analyst Blog Highlights: JPM, PYPL, NVO, RHHBY and TM - www.zacks.com
|2020-09-18 $ 69.44 (-0.19%)|
Top Analyst Reports for JPMorgan, PayPal & Novo Nordisk - www.zacks.com
SNY vs. NVO: Which Stock Should Value Investors Buy Now? - www.zacks.com
|2020-09-16 $ 67.96 (0.06%)|
Lilly Drug Gets Fast Track to Improve Heart Attack Outcome - www.zacks.com
|2020-09-09 $ 66.65 (2.81%)|
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY - www.zacks.com
|2020-09-08 $ 64.83 (-0.43%)|
Top Research Reports for Disney, Novo Nordisk & BHP - www.zacks.com
|2020-09-04 $ 65.11 (0.05%)|
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity - www.zacks.com
|2020-08-17 $ 66.86 (1.66%)|
|2020-08-14 $ 65.77 (-1.63%)|
Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies - www.zacks.com
|2020-08-13 $ 66.86 (-0.34%)|
3 Top Diabetes Stocks to Buy in August - www.fool.com
|2020-08-06 $ 63.69 (-2.15%)|
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss - www.zacks.com
|2020-07-28 $ 67.28 (-0.19%)|
Novo, Roche Scored Highest Returns on Invested Capital - GuruFocus.com
|2020-07-13 $ 65.15 (-0.44%)|
Top Stock Reports for Alphabet, Merck & Medtronic - www.zacks.com
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio - www.zacks.com
2 Top Diabetes Stocks to Buy Right Now - www.fool.com
|2020-06-22 $ 67.94 (0.58%)|
Novo Nordisk Completes Two Studies on Obesity Candidate - www.zacks.com
|2020-06-17 $ 66.72 (2.19%)|
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study - www.zacks.com
|2020-06-12 $ 64.61 (0.29%)|
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus - www.zacks.com
Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash - www.zacks.com
|2020-06-10 $ 66.56 (2.99%)|
Lilly Begins Cardiovascular Outcomes Study on Tirzepatide - www.zacks.com
|2020-06-01 $ 65.7 (-0.36%)|
|2020-05-29 $ 65.94 (1.51%)|
Top Stock Reports for Novo Nordisk, IBM & Honeywell - www.zacks.com
|2020-05-22 $ 64.83 (0.02%)|
|2020-05-13 $ 63.25 (1.14%)|
|2020-05-08 $ 62.76 (0.72%)|
|2020-05-07 $ 62.31 (0.53%)|
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates - www.zacks.com
|2020-04-30 $ 63.33 (0.46%)|
SNY vs. NVO: Which Stock Is the Better Value Option? - www.zacks.com
|2020-04-29 $ 63.04 (-2.4%)|
|2020-04-28 $ 64.59 (-0.84%)|
Tracking Q2 and Full-Year 2020 Earnings Estimates - www.zacks.com
|2020-04-21 $ 64.1 (-0.02%)|
|2020-04-14 $ 59.79 (1.61%)|